AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35704597
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg, once daily)
Trial: 616858603
Drug: Self-management intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management intervention along with conventional drug therapy
Trial: 616858603
Drug: Standard outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard outpatient care and conventional drug therapy
Trial: 35717855
Drug: Group-based Compassion-Focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based Compassion-Focused Therapy (CFT)
Trial: 36231747
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (L. salivarius)
Trial: 33207015
Drug: SQ tree
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ tree SLIT-tablet (containing birch extract)
Trial: 32573396
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (light monotherapy)
Trial: 32573396
Drug: Fluoxetine (fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (fluoxetine monotherapy)
Trial: 35637038
Drug: Topical Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cannabidiol (CBD) 6.2 mg/mL with shea butter, applied twice daily for 2 weeks
Trial: 35637038
Drug: Control: Shea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Shea butter alone, applied twice daily for 2 weeks
Trial: 32111479
Drug: Antioxidant formulation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant formulation (n = 85) containing 500 mg of vitamin C, 400 mg of vitamin E, 0.20 mg of selenium, 1,000 mg of l-carnitine, 20 mg of zinc, 1,000 μg of folic acid, 10 mg of lycopene daily
Trial: 32111479
Drug: Antioxidant formulation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant formulation
Trial: 34391309
Drug: Whole-Body Vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-Body Vibration (WBV) therapy, 12 sessions, amplitude of 3 mm, frequency of 20 Hz, 6 days/week for 2 weeks
Trial: 32216204
Drug: Yishen Zhuangyang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishen Zhuangyang Cream (YZC)
Trial: 38874763
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy
Trial: 33595105
Drug: 3D CNN
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D CNN model for pancreas segmentation at full dose CT
Trial: 33595105
Drug: 3D CNN
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D CNN model for pancreas segmentation at reduced dose CT
Trial: 33595105
Drug: 3D CNN
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D CNN model vs R1 at full dose CT
Trial: 33595105
Drug: 3D CNN
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D CNN model vs R2 at full dose CT
Trial: 33595105
Drug: 3D CNN
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D CNN model vs R1 at reduced dose CT
Trial: 33595105
Drug: 3D CNN
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D CNN model vs R2 at reduced dose CT
Trial: 34373322
Drug: Higher rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher rates of fluid infusion
Trial: 32306925
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) in control wards.
Trial: 36381249
Drug: Denosumab biosimilar
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab biosimilar (LY06006) 60 mg subcutaneously every 6 months for 1 year
Trial: 33573699
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous vitamin C (HDIVC) 6 g daily
Trial: 34100922
Drug: Apremilast 20
RxNorm normalized name: apremilast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 20 mg
Trial: 32333486
Drug: Acceptance-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based group behavioral therapy (ABBT)
Trial: 32333486
Drug: Standard nondirective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nondirective supportive group therapy (NDST)
Trial: 36889873
Drug: Daily remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily remote monitoring data
Trial: 32383227
Drug: Oral Nicotinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nicotinamide (NAM) supplementation
Trial: 34562564
Drug: Low-dose Guizhi
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Guizhi Fuling Wan
Trial: 34562564
Drug: Conventional-dose Guizhi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose Guizhi Fuling Wan
Trial: 34562564
Drug: Sub-effective dose
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-effective dose control (not explicitly named)
Trial: 34434003
Drug: BMAC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMAC injection followed by PRP injection
Trial: 34434003
Drug: Gel-One® cross-linked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-One® cross-linked hyaluronate (HA) injection
Trial: 32445557
Drug: MG+SG (compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG+SG (compression with foam roller/ball + static stretching)
Trial: 32445557
Drug: MG (compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG (compression only)
Trial: 35049354
Drug: Automated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated insulin delivery (AID)
Trial: 34981778
Drug: Sustained oral
RxNorm normalized name: Sustain Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained oral peanut protein exposure
Trial: 34981778
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of oral peanut protein exposure
Trial: 32666822
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 24 months
Trial: 34024878
Drug: Atorvastatin (statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (statin group)
Trial: 35022147
Drug: Negative‐Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative‐Pressure Wound Therapy (NPWT)
Trial: 32969513
Drug: Laplace-based algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laplace-based algorithm for treatment allocation
Trial: 32035020
Drug: Fulvestrant plus
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant plus capivasertib (400 mg orally twice daily on an intermittent weekly schedule)
Trial: 33798304
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with acupuncture at acupoints of limbs
Trial: 33274895
Drug: Foliar application
RxNorm normalized name: Folicare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foliar application of algae at 8 g L‐1
Trial: 33274895
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (foliar water)
Trial: 34412973
Drug: HCG (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG (500 IU in 0.1 ml of tissue culture media)
Trial: 34412973
Drug: Culture media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture media (0.1 ml of tissue culture media)
Trial: 33400432
Drug: High-voltage PRF
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-voltage PRF combined with low-temperature CRF (70 V, 42°C, 2 Hz, pulse width 20 ms, treatment time 600 s; CRF at 60°C, treatment time 270 s)
Trial: 33400432
Drug: High-voltage PRF
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-voltage PRF only (70 V, 42°C, 2 Hz, pulse width 20 ms, treatment time 600 s)
Trial: 32538008
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) applied at specific acupoints on days 1, 2, 3, 5, 8, 14, 21, and 28 of chemotherapy, 30 minutes each time, once a day.
Trial: 32538008
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group received DiyuShengbai tablets before chemotherapy, 2-3 tablets each time, 3 times a day.
Trial: 32538008
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (chemotherapy with gemcitabine and cisplatin plus routine care)
Trial: 33189857
Drug: tDCS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS with sham MCAT treatment
Trial: 32571263
Drug: Individuals self-identifying
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals self-identifying as having or having had a prescription drug abuse issue
Trial: 36336989
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (hydroxypropyl chitosan‐based 80 mg/g ciclopirox nail lacquer)
Trial: 33567047
Drug: NPWT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPWT + PRP gel
Trial: 32303260
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy program (10 two-hour weekly sessions)
Trial: 33861679
Drug: Sabin inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabin inactivated poliovirus vaccine (sIPV)
Trial: 33722384
Drug: Topical ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ivermectin 1% cream and placebo
Trial: 35180260
Drug: Clown visits
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clown visits by RED NOSES Clowndoctors Austria on a weekly basis over four consecutive weeks
Trial: 32542869
Drug: Transepidermal application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transepidermal application of CO2 (twice daily for 1 week)
Trial: 32542869
Drug: Formulation containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation containing hydrochloric acid (control)
Trial: 35871338
Drug: Multimodal exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal exercise program with omega-3 (900 mg EPA, 600 mg DHA), vitamin D (1000 IU), and protein (20 g) supplement (n=73)
Trial: 35871338
Drug: Multimodal exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal exercise program with omega-3, vitamin D, and protein supplement (n=73)
Trial: 38795716
Drug: Bimekizumab 320
RxNorm normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 320 mg every 4 weeks
Trial: 33549192
Drug: Bimekizumab 320
RxNorm normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 320 mg every 8 weeks
Trial: 33407609
Drug: Tomato sauce
RxNorm normalized name: Nutritional Supplement Oral Food, Solid [DIETARY SPECIALTIES TOMATO SAUCE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato sauce (OsteoCol) 150 ml/day
Trial: 33407609
Drug: Sterol-enriched yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterol-enriched yogurt (1.6 g/die)
Trial: 32159711
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus immediate access to Deprexis
Trial: 32159711
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus delayed access to Deprexis (after 8 weeks)
Trial: 34471452
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (boxing/martial arts)
Trial: 32356115
Drug: Abatacept 125
RxNorm normalized name: abatacept 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 125 mg weekly for 24 weeks
Trial: 36128636
Drug: Continuous entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous entecavir monotherapy
Trial: 33278364
Drug: Perturbation-based pinch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perturbation-based pinch task training (20 minutes per session, twice a week for 6 weeks)
Trial: 33278364
Drug: Task-specific motor
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-specific motor training (20 minutes per session, twice a week for 6 weeks)
Trial: 39222896
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medical therapy alone)
Trial: 35704394
Drug: OnabotulinumtoxinA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA (all higher doses)
Trial: 35271478
Drug: Enteral lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral lactoferrin supplementation (100 mg/day until PMA of 36 weeks or discharge)
Trial: 33155461
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen and IM pethidine (Group A)
Trial: 33155461
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen and IV parecoxib (Group B)
Trial: 33155461
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen monotherapy (Group C)
Trial: 35653761
Drug: Daily skin-to-skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily skin-to-skin contact (SSC) for 1 hour daily for the first 5 weeks postpartum
Trial: 35653761
Drug: Daily skin-to-skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily skin-to-skin contact (SSC)
Trial: 34385241
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg/day plus LHRHa
Trial: 35371278
Drug: ESWT combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESWT combined with wIRA therapy
Trial: 35371278
Drug: wIRA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wIRA therapy (Control)
Trial: 32609979
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for 3 days
Trial: 35934873
Drug: Emergency umbilical
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency umbilical button cannula (EUC) using lateral umbilical cord incision (L-EUC)
Trial: 32917473
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) with low-energy flux density (0.05–0.30 mJ/mm2)
Trial: 32605536
Drug: Daily questioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily questioning
Trial: 33545548
Drug: Bufei Yishen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bufei Yishen formula (BYF) combined with conventional Western medicine
Trial: 33545548
Drug: Key active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Key active molecules (KAM) of BYF
Trial: 33966913
Drug: Buccal chamfer
RxNorm normalized name: HOLDING CHAMBER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal chamfer
Trial: 32888370
Drug: Secukinumab (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (standard dose)
Trial: 36040362
Drug: 99.9% pure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99.9% pure CBD (200 mg/day for 2 weeks, then 300 mg/day for 10 weeks)
Trial: 33441010
Drug: Inoculation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculation with 1 × 10^6/ml spore suspension of Fusarium redolens
Trial: 35164986
Drug: FINLAY-FR-1 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FINLAY-FR-1 (50 µg d-RBD plus outer membrane vesicles from N. meningitidis)
Trial: 35164986
Drug: FINLAY-FR-1A-50 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FINLAY-FR-1A-50 (50 µg d-RBD, three doses)
Trial: 35164986
Drug: FINLAY-FR-1A-25 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FINLAY-FR-1A-25 (25 µg d-RDB, three doses)
Trial: 32538747
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid parenteral nutrition
Trial: 32538747
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (equal-nitrogen and equal-calorie enteral and parenteral nutrition)
Trial: 33348306
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 20 minutes, done for three consecutive days.
Trial: 35421086
Drug: Morning bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning bright light therapy (10,000 lux at the eye) for 60 minutes every morning for 4 weeks
Trial: 35421086
Drug: Morning bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning bright light therapy
Trial: 35183882
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of boron citrate twice a day
Trial: 35183882
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of oleoylethanolamide twice a day
Trial: 35183882
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (5 mg of boron citrate and 200 mg of oleoylethanolamide)
Trial: 35183882
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments without any study medications (Control)
Trial: 35781459
Drug: Anifrolumab (Saphnelo®)
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab (Saphnelo®) administered as an intravenous infusion, 300 mg over a 30-minute period, every 4 weeks
Trial: 32377783
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g TXA (intravenous)
Trial: 32377783
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g TXA (topical)
Trial: 32377783
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g TXA (combined intravenous + topical)
Trial: 32377783
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g TXA (combined + group)
Trial: 34137514
Drug: Aomei meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aomei meloxicam (15 mg)
Trial: 34137514
Drug: Mobic meloxicam
RxNorm normalized name: meloxicam Oral Tablet [Mobic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobic meloxicam (15 mg)
Trial: 32700572
Drug: Immediate initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate initiation of lipid lowering (treatment for 30 years) in 40- to 49-year-old patients with non-HDL-C ≥160 mg/dL
Trial: 32700572
Drug: Delaying lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delaying lipid lowering by 10 years (treatment for 20 years)
Trial: 32700572
Drug: Delaying lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delaying lipid lowering by 20 years (treatment for 10 years)
Trial: 35704027
Drug: 3.2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 g/day sunflower oil (placebo)
Trial: 32859542
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus physical therapy
Trial: 35440469
Drug: Colchicine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (500 µg daily for 14 days)
Trial: 34285701
Drug: Berberis integerrima
RxNorm normalized name: BERBERIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberis integerrima fruit extract (1000 mg daily, 5 ml twice daily)